<DOC>
	<DOCNO>NCT01345357</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) CEP-9722 combination gemcitabine cisplatin patient advance solid tumor mantle cell lymphoma .</brief_summary>
	<brief_title>Study CEP-9722 Combination With Gemcitabine Cisplatin Patients With Advanced Solid Tumors Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Written inform consent obtain . The patient either histologically cytologically confirm malignant advance solid tumor mantle cell lymphoma ( experienced failure least 1 previous therapy ) patient may benefit combination gemcitabine cisplatin . The patient measurable nonmeasurable disease evaluate accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 guideline . The patient man woman least 18 year age . The patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . The patient life expectancy 12 week . The patient adequate hematologic assessment adequate renal hepatic function specify study protocol The patient audiogram result without clinically significant abnormality . The patient may chemotherapy provide least 3 week elapse prior sequelae resolve . If patient prior radiation ( curative palliative ) prior treatment nitrosoureas , minimum 4 week 6 week , respectively , must elapse treatment CEP9722 . The patient immunotherapy , include monoclonal antibody therapy , least 4 week hormonal therapy least 1 week , exception patient prostate cancer , may continue hormonal therapy . Written inform consent obtain . Agreement woman childbearing potential ( surgically sterile 2 year postmenopausal ) use medically accept method contraception continue use method duration study 90 day participation study . Acceptable method contraception include abstinence , barrier method spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . Agreement men surgically sterile capable produce offspring practice abstinence use barrier method birth control , continue use method duration study 6 month participation study . With exception cancer , patient serious uncontrolled surgical , medical , psychiatric history could prevent compliance study procedure , compromise integrity study . The patient protocol specify risk factor Torsade de Pointes The patient brain lesion require systemic therapy corticosteroid anticonvulsive agent . The patient previous hypersensitivity reaction 1 component CEP9722 , gemcitabine , cisplatin drug product . The patient pregnant breastfeed woman . ( Any woman become pregnant study withdrawn study . ) The patient participate another interventional clinical study time enrollment participate another interventional clinical study within 4 week prior enrollment . The patient malabsorption syndrome and/or prior gastrectomy The patient concomitant uncontrolled and/or chronic infection severe systemic disease . The patient previous treatment another poly ( adenosine diphosphateribose ) polymerase ( PARP ) inhibitor . The patient unable swallow tablet . The patient interrupt continuous treatment proton pump inhibitor and/or H2 receptor antagonist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Antineoplastic agent</keyword>
</DOC>